Posted on May 7 ยท Posted in News

Nexgenia was awarded a Phase 1 SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) in February 2016. Nexgenia is collaborating with the Fred Hutchinson Cancer Research Center on this proposal. The project helps to commercialize our reagents for CAR T cell manufacturing.